Advanced Search

Project: Three types of hypoglycemic agents (DPP- 4Is, GLP-1RAs, SGLT-2Is) for patients with type 2 diabetes: effectiveness and safety evaluation network meta-analysis

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Extraction Form Feng Sun 1


Associated Studies (each link opens a new tab)

Title Author Year
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Bays HE., Weinstein R., Law G., Canovatchel W. 2014
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Barnett AH., Mithal A., Manassie J., Jones R., Rattunde H., Woerle HJ., Broedl UC. 2014
Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol. Balis DA., Tong C., Meininger G. 2014
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Bailey CJ., Iqbal N., T'joen C., List JF. 2012
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. Bailey CJ., Gross JL., Hennicken D., Iqbal N., Mansfield TA., List JF. 2013
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Aso Y., Kato K., Sakurai S., Kishi H., Shimizu M., Jojima T., Iijima T., Maejima Y., Shimomura K., Usui I. 2019
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Aronson R., Frias J., Goldman A., Darekar A., Lauring B., Terra SG. 2018
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. Araki E., Onishi Y., Asano M., Kim H., Ekholm E., Johnsson E., Yajima T. 2016
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Amin NB., Wang X., Jain SM., Lee DS., Nucci G., Rusnak JM. 2015




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/